Maxcyte (MXCT) Current Assets (2020 - 2026)

Maxcyte (MXCT) has reported Current Assets for 7 consecutive years, with $121.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 15.32% year-over-year to $121.3 million in Q2 2026; TTM through Jun 2026 was $121.3 million, a 15.32% decrease from a year earlier, with the FY2025 full-year figure at $118.4 million, down 31.05% from the prior year.
• Current Assets was $121.3 million for Q2 2026 at Maxcyte, down from $122.9 million in the prior quarter.
• Over five years, Current Assets peaked at $265.8 million in Q1 2022 and troughed at $118.4 million in Q4 2025.
• A 5-year average of $188.9 million and a median of $177.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 204.67% in 2022 and slumped 31.05% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $252.3 million in 2022, then declined by 24.61% to $190.2 million in 2023, then dropped by 9.73% to $171.7 million in 2024, then tumbled by 31.05% to $118.4 million in 2025, then advanced by 2.45% to $121.3 million in 2026.
• The last three Current Assets figures came in at $121.3 million (Q2 2026), $122.9 million (Q1 2026), and $118.4 million (Q4 2025), per Business Quant data.